Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study
Amy S. Paller, Ying Hong, Emily M. Becker, et al.
Journal of the American Academy of Dermatology (2019) Vol. 82, Iss. 2, pp. 389-397
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients
Matteo Megna, Elisa Camela, Teresa Battista, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 1, pp. 25-41
Closed Access | Times Cited: 42
Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial
Loretta Fiorillo, Emily Becker, R. de Lucas, et al.
Journal of the American Academy of Dermatology (2024) Vol. 90, Iss. 6, pp. 1232-1239
Open Access | Times Cited: 13
PDE4 inhibitors: potential protective effects in inflammation and vascular diseases
Tianfei Fan, Wenjing Wang, Yao Wang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 10
Successful Treatment of Palmoplantar Psoriasis With Apremilast in an Immunosuppressed Pediatric Patient on Concurrent Biologic Therapy
Shawheen J. Rezaei, Danny W. Linggonegoro, Shehla Admani
Pediatric Dermatology (2025)
Closed Access | Times Cited: 1
Emerging treatments for dermatologic diseases in infants, children, and adolescents: a systematic review of clinical trials on biologics and small molecule inhibitors
Alireza Jafarzadeh, Elham Behrangi, Mina Khosravi, et al.
Inflammopharmacology (2025) Vol. 33, Iss. 4, pp. 1617-1672
Closed Access | Times Cited: 1
Phosphodiesterase-4 Inhibition in the Management of Psoriasis
Erika L. Crowley, Melinda Gooderham
Pharmaceutics (2023) Vol. 16, Iss. 1, pp. 23-23
Open Access | Times Cited: 16
Apremilast in dermatology: A review of literature
David Nassim, Ali Alajmi, Abdulhadi Jfri, et al.
Dermatologic Therapy (2020) Vol. 33, Iss. 6
Open Access | Times Cited: 39
Poor-tasting pediatric medicines: Part 1. A scoping review of their impact on patient acceptability, medication adherence, and treatment outcomes
Sejal R. Ranmal, Jennifer Walsh, Catherine Tuleu
Frontiers in Drug Delivery (2025) Vol. 5
Open Access
The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
Murlidhar Rajagopalan, Sunil Dogra, Abir Saraswat, et al.
Psoriasis Targets and Therapy (2021) Vol. Volume 11, pp. 109-122
Open Access | Times Cited: 17
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis
Jonathan D. Greenzaid, Steven R. Feldman
Clinical Pharmacokinetics (2024)
Closed Access | Times Cited: 2
Small Molecules in the Management of Psoriasis and Psoriatic Arthritis
Venkata Chalam Konakanchi, Bikash Ranjan Kar, Dharshini Sathishkumar, et al.
Indian Journal of Dermatology (2024) Vol. 69, Iss. 3, pp. 249-255
Open Access | Times Cited: 2
Targeted Therapy for Pediatric Psoriasis
Miguel Nogueira, Amy S. Paller, Tiago Torres
Pediatric Drugs (2021) Vol. 23, Iss. 3, pp. 203-212
Closed Access | Times Cited: 14
Perspectives on the pharmacological management of psoriasis in pediatric and adolescent patients
E. Mahé, M. Amy de la Bretèque, C. Phan
Expert Review of Clinical Pharmacology (2021) Vol. 14, Iss. 7, pp. 807-819
Closed Access | Times Cited: 13
Clinical pharmacokinetics and pharmacodynamics of oral systemic nonbiologic therapies for psoriasis patients
Justin M. Eichinger, Divya M. Shan, Jonathan D. Greenzaid, et al.
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 4, pp. 249-262
Closed Access | Times Cited: 1
Apremilast: First Pediatric Approval
Hannah A. Blair
Pediatric Drugs (2024)
Closed Access | Times Cited: 1
Off-Label Treatments for Pediatric Psoriasis: Lessons for the Clinic
Morten Bahrt Haulrig, Claus Zachariae, Lone Skov
Psoriasis Targets and Therapy (2021) Vol. Volume 11, pp. 1-20
Open Access | Times Cited: 8
Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics
Angelo Ruggiero, Antonio Portarapillo, Matteo Megna, et al.
Pediatric Health Medicine and Therapeutics (2023) Vol. Volume 14, pp. 435-451
Open Access | Times Cited: 3
Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis
C. Phan, N. Bénéton, J. Delaunay, et al.
Drugs & Aging (2020) Vol. 37, Iss. 9, pp. 657-663
Closed Access | Times Cited: 7
An update on the safety of apremilast for the treatment of plaque psoriasis
Eran Shavit, Neil H. Shear
Expert Opinion on Drug Safety (2020) Vol. 19, Iss. 4, pp. 403-408
Closed Access | Times Cited: 6
Phosphodiesterase 4 Inhibition in the Management of Psoriasis
Erika L. Crowley, Melinda Gooderham
(2023)
Open Access | Times Cited: 2
Therapeutic challenges in managing pediatric psoriasis
Yamila Goenaga-Vázquez, Kyle C. Lauck, Adelaide A. Hebert
International Journal of Women’s Dermatology (2020) Vol. 7, Iss. 3, pp. 314-318
Open Access | Times Cited: 5
Advances in small molecule inhibitors for treatment of psoriasis
Wenjuan Chen, Chen Peng, Jiajing Lu, et al.
Chinese Medical Journal (2021) Vol. 134, Iss. 11, pp. 1364-1366
Open Access | Times Cited: 4
Biologics in pediatric dermatology
Manjyot Gautam, Ratnakar Shukla
Indian Journal of Paediatric Dermatology (2021) Vol. 22, Iss. 2, pp. 107-107
Open Access | Times Cited: 4
Apremilast Uses and Relevance to the Military
Nathanael E. Hathaway
Cutis (2021), Iss. Vol. 107 No. 4
Open Access | Times Cited: 4
Risk assessment of therapeutic agents under consideration to treat COVID‐19 in paediatric patients and pregnant women
Jeffrey S. Barrett
British Journal of Clinical Pharmacology (2020) Vol. 87, Iss. 9, pp. 3462-3480
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top